Current Panorama and Challenges for Neoadjuvant Cancer Immunotherapy

Area of Science:

• Oncology
• Immunology
• Cancer Research

Background:

• Immune checkpoint inhibitors (ICI) are a novel therapeutic strategy to overcome cancer immune evasion.
• The established efficacy of ICI in metastatic disease has prompted investigation into neoadjuvant applications.
• Several tumor types, including melanoma, non-small cell lung cancer, breast, and bladder cancer, are being evaluated for neoadjuvant ICI therapy.

Purpose of the Study:

• To summarize the current evidence on the efficacy of neoadjuvant immune checkpoint inhibitors (ICI) across various cancer types.
• To identify and discuss unresolved challenges associated with neoadjuvant ICI treatment strategies.

Main Methods:

• Review of current scientific literature and clinical evidence.
• Synthesis of data regarding neoadjuvant ICI efficacy in melanoma, non-small cell lung cancer, breast cancer, and bladder cancer.
• Identification of key challenges through expert discussion and literature analysis.

Main Results:

• Neoadjuvant ICI demonstrates efficacy in several tumor types, offering a promising approach to cancer treatment.
• Evidence suggests potential benefits in the neoadjuvant setting, preceding definitive treatment.
• Key challenges include determining the optimal role of adjuvant therapy post-neoadjuvant ICI, efficacy in tumors with specific oncogenic dependencies, and standardizing pathological assessment methods.

Conclusions:

• Neoadjuvant immune checkpoint inhibitors represent a significant advancement in cancer therapy.
• Addressing challenges related to adjuvant treatment, specific tumor vulnerabilities, and pathological evaluation is crucial for maximizing the benefit of neoadjuvant ICI.
• Further research and standardization are necessary to optimize neoadjuvant ICI protocols and improve patient outcomes.